TACSTD2 and ovarian carcinoma: Based on this analysis, we found that TACSTD2 modulates the PI3K/AKT pathway through the Rap1 signalling pathway, thereby influencing AKT phosphorylation, and subsequently influencing ovarian cancer cell sensitivity to platinum-based treatment (Figure S4D).